In the race to forge the next Keytruda from PD-(L)1xVEGF bispecific antibodies, Pfizer and the BioNTech-Bristol Myers Squibb alliance are split on how to position overall survival—the gold-standard ...

German biotech Tubulis has shared updated data from a phase 1 study of the antibody-drug conjugate (ADC) TUB-040, the star behind Gilead’s decision to buy the company for $3.15 billion upfront in A | ...

Pfizer is paying Innovent $650 million upfront to partner on cancer drug development, following Bristol Myers Squibb by ...

Hoth Therapeutics’ search for salvation in the stars appears to have been rewarded by investors, as the company’s stock ...

After treatment with bepirovirsen, however, 19% of patients achieved the strictly defined “functional cure” criteria. For the ...

Novartis may be launching an array of vehicles to shuttle drugs across the blood-brain barrier, but executives told Fierce ...

Irish CRO Icon has closed the book on its investigation into its accounting practices and restated its consolidated ...

The FDA has delayed its approval decision on Beren Therapeutics’ rare disease drug candidate, extending the asset’s long path ...

D&D Pharmatech has linked its GLP-1/glucagon dual receptor agonist to improvements in liver health, keeping the Korean ...

AstraZeneca has shared data it believes can rescue anselamimab from a phase 3 failure, linking the drug candidate to a 62% improvement in survival among a prespecified subgroup of ...

Human Longevity, which is seeking to use biology and genomics to boost the human lifespan, has launched a new company called ...

Bristol Myers Squibb may be leading the way when it comes to pursuing cereblon E3 ligase modulator (CELMoD) drugs, but today, the pharma is standing tall.  | Bristol Myers Squibb may have gone big in ...